{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:09:51Z","timestamp":1777507791853,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170722"],"award-info":[{"award-number":["82170722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04182-7","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T06:02:35Z","timestamp":1723528955000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing prognostic guidance in renal light-chain amyloidosis: a new staging system incorporating pathological characters"],"prefix":"10.1007","volume":"57","author":[{"given":"Yan","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiayin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"1","key":"4182_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.6004\/jnccn.2022.7077","volume":"21","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Gertz MA, Muchtar E (2023) Immunoglobulin light chain amyloidosis: diagnosis and risk assessment. J Natl Compr Canc Netw 21(1):83\u201390","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"4182_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock TP, Yan T, Chang E et al (2018) Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2(10):1046\u20131053","journal-title":"Blood Adv"},{"issue":"1","key":"4182_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","volume":"17","author":"N Kumar","year":"2022","unstructured":"Kumar N, Zhang NJ, Cherepanov D et al (2022) Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis 17(1):278","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4182_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A (2020) Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA 324(1):79\u201389","journal-title":"JAMA"},{"key":"4182_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100720","volume":"45","author":"C Varga","year":"2021","unstructured":"Varga C, Dorbala S, Lousada I et al (2021) The diagnostic challenges of cardiac amyloidosis: a practical approach to the two main types. Blood Rev 45:100720","journal-title":"Blood Rev"},{"issue":"1","key":"4182_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","volume":"13","author":"G Palladini","year":"2023","unstructured":"Palladini G, Sch\u00f6nland S, Merlini G et al (2023) The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J 13(1):19","journal-title":"Blood Cancer J"},{"issue":"1","key":"4182_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-022-02752-4","volume":"23","author":"P Zhang","year":"2022","unstructured":"Zhang P, Chen X, Zou Y et al (2022) Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review. BMC Nephrol 23(1):127","journal-title":"BMC Nephrol"},{"issue":"5","key":"4182_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjh.16094","volume":"187","author":"JM Sloan","year":"2019","unstructured":"Sloan JM (2019) Lessons in long term survival from AL amyloidosis. Br J Haematol 187(5):557\u2013558","journal-title":"Br J Haematol"},{"issue":"1","key":"4182_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/13506129.2019.1672650","volume":"27","author":"A Angel-Korman","year":"2020","unstructured":"Angel-Korman A, Jaberi A, Sanchorawala V et al (2020) The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid 27(1):17\u201324","journal-title":"Amyloid"},{"issue":"3","key":"4182_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/13506129.2017.1360272","volume":"24","author":"S Rubinstein","year":"2017","unstructured":"Rubinstein S, Cornell RF, Du L et al (2017) Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid 24(3):205\u2013211","journal-title":"Amyloid"},{"issue":"3","key":"4182_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/ckj\/sfaa019","volume":"14","author":"JJ Hoelbeek","year":"2021","unstructured":"Hoelbeek JJ, Kers J, Steenbergen EJ et al (2021) Renal amyloidosis: validation of a proposed histological scoring system in an independent cohort. Clin Kidney J 14(3):855\u2013862","journal-title":"Clin Kidney J"},{"issue":"15","key":"4182_CR12","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P et al (2014) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124(15):2325\u20132332","journal-title":"Blood"},{"issue":"7","key":"4182_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ajh.24738","volume":"92","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, Gavriatopoulou M, Roussou M et al (2017) Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. Am J Hematol 92(7):632\u2013639","journal-title":"Am J Hematol"},{"issue":"4","key":"4182_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol 79(4):319\u2013328","journal-title":"Am J Hematol"},{"issue":"12","key":"4182_CR15","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"4182_CR16","unstructured":"Kumar SK, Callander NS, Adekola K, et al. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(1):67\u201381."},{"issue":"7","key":"4182_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","volume":"104","author":"T Dittrich","year":"2019","unstructured":"Dittrich T, Benner A, Kimmich C et al (2019) Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104(7):1451\u20131459","journal-title":"Haematologica"},{"issue":"10","key":"4182_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H et al (2015) Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther 32(10):920\u2013928","journal-title":"Adv Ther"},{"issue":"4","key":"4182_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ejh.13679","volume":"107","author":"LL Hester","year":"2021","unstructured":"Hester LL, Gifkins DM, K MB et al (2021) Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol 107(4):428\u2013435","journal-title":"Eur J Haematol"},{"issue":"1","key":"4182_CR20","doi-asserted-by":"publisher","first-page":"2227425","DOI":"10.1080\/07853890.2023.2227425","volume":"55","author":"M Chen","year":"2023","unstructured":"Chen M, Liu J, Wang X et al (2023) Diagnosis for Chinese patients with light chain amyloidosis: a scoping review. Ann Med 55(1):2227425","journal-title":"Ann Med"},{"issue":"2","key":"4182_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12185-023-03617-8","volume":"118","author":"W Xie","year":"2023","unstructured":"Xie W, Wang Q, Zhou F et al (2023) Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study. Int J Hematol 118(2):231\u2013241","journal-title":"Int J Hematol"},{"issue":"4","key":"4182_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):117\u2013314","journal-title":"Kidney Int"},{"issue":"10","key":"4182_CR23","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","volume":"32","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Dispenzieri A, Leung N et al (2018) Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia 32(10):2240\u20132249","journal-title":"Leukemia"},{"issue":"25","key":"4182_CR24","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F et al (2019) A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 134(25):2271\u20132280","journal-title":"Blood"},{"issue":"3","key":"4182_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5414\/CN107162","volume":"79","author":"H Okuyama","year":"2013","unstructured":"Okuyama H, Yamaya H, Fukusima T et al (2013) A patient with persistent renal AL amyloid deposition after clinical remission by HDM\/SCT therapy. Clin Nephrol 79(3):233\u2013236","journal-title":"Clin Nephrol"},{"issue":"12","key":"4182_CR26","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1093\/ndt\/gfg436","volume":"18","author":"M Zeier","year":"2003","unstructured":"Zeier M, Perz J, Linke RP et al (2003) No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant 18(12):2644\u20132647","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"4182_CR27","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","volume":"138","author":"CV Edwards","year":"2021","unstructured":"Edwards CV, Rao N, Bhutani D et al (2021) Phase 1a\/b study of monoclonal antibody CAEL-101 (11\u20131F4) in patients with AL amyloidosis. Blood 138(25):2632\u20132641","journal-title":"Blood"},{"issue":"14","key":"4182_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.2023021311","volume":"142","author":"A Huart","year":"2023","unstructured":"Huart A (2023) Birtamimab: a new amyloidosis treatment? Blood 142(14):1178\u20131180","journal-title":"Blood"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04182-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04182-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04182-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:09:35Z","timestamp":1735873775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04182-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["4182"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04182-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of Xijing Hospital (ethical number: KY20213027-1). In addition, this study was conducted in accordance with the standards of the 1964 Declaration of Helsinki and its later revisions or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required because of the nature of the retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}